Emergency planned re-infusion therapy and hospitalisation for community-acquired pneumonia: a retrospective case-control study

被引:0
|
作者
Chen, Sheng-Xian [1 ]
Yang, Zhi-Kai [1 ]
Lin, Lin [2 ]
Liao, Hou-Zhen [1 ]
Xiang, Xiao-Ting [1 ]
Liu, Di [1 ]
Huang, Jian-Shan [1 ]
机构
[1] Xiamen Chang Gung Hosp, Dept Emergency Clin, 123 Xiafei Rd, Xiamen, Fujian, Peoples R China
[2] Xiamen Chang Gung Hosp, Dept Gen Med, Xiamen, Peoples R China
关键词
LOW-RISK PATIENTS; LEVOFLOXACIN; GUIDELINES; MANAGEMENT; SEVERITY; ADULTS;
D O I
10.7189/jogh.15.04044
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Community-acquired pneumonia (CAP) is a frequent reason for emergency department visits and leads to increased direct medical costs, particularly due to hospitalisation. This study aims to examine the differences between emergency planned re-infusion therapy and hospitalisation in patients with CAP. Methods This retrospective case-control study involved 1889 CAP patients treated at the Emergency Internal Medicine Department of Class A tertiary Hospital in China from 1 January 2020 to 31 December 2022. Patients were divided into groups receiving either emergency planned re-infusion therapy or hospitalisation. Independent sample t tests and chi 2 tests were used to compare the clinical outcomes and economic impacts between the two groups across different pneumonia severity index (PSI) classifications.<br /> Results The study enrolled 1889 CAP patients. For PSI I-II patients, the improvement rates were 99.51% in the emergency planned re-infusion therapy group and 99.69% in the hospitalisation group, showing no statistically significant difference (P> 0.05). Similarly, no significant difference was observed for PSI III patients (84.16 vs. 89.82%). However, significant differences emerged for PSI IV patients, with improvement rates of 50% in the emergency planned re-infusion therapy group and 90.59% in the hospitalisation group (P < 0.001). Statistically significant differences were also noted in treatment duration (5.13 +/- 1.65 days vs. 7.60 +/- 3.93 days, P < 0.001) and total treatment costs (1921.57 Chinese Yuan (CNY) +/- 923.16 vs. 9083.80 CNY +/- 3583.55, P<0.001) between the two groups.<br /> Conclusions Emergency planned re-infusion therapy for CAP is an effective and cost-efficient alternative that can reduce both treatment duration and costs, particularly for patients with PSI I-III. It is recommended that emergency physicians give priority to emergency re-infusion therapy for patients with PSI I-III. In addition, it is recommended that hospitals strengthen the classification and treatment training programmes for emergency department physicians to recognise the patients with PSI I-IV.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Early discontinuation of combination antibiotic therapy in severe community-acquired pneumonia: a retrospective cohort study
    Pauline Guillot
    Flora Delamaire
    Arnaud Gacouin
    Benoit Painvin
    Caroline Piau
    Florian Reizine
    Mathieu Lesouhaitier
    Jean-Marc Tadié
    Adel Maamar
    BMC Infectious Diseases, 23
  • [32] Early discontinuation of combination antibiotic therapy in severe community-acquired pneumonia: a retrospective cohort study
    Guillot, Pauline
    Delamaire, Flora
    Gacouin, Arnaud
    Painvin, Benoit
    Piau, Caroline
    Reizine, Florian
    Lesouhaitier, Mathieu
    Tadie, Jean-Marc
    Maamar, Adel
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [33] Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting
    Malcolm, C
    Marrie, TJ
    ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (07) : 797 - 802
  • [34] Severe Community-Acquired Pneumonia in Healthy Adults: A Multicentric Retrospective Study
    Fernandez Acquier, M.
    Labato, M.
    Monteverde, A.
    Serrano, R.
    Moyano, V.
    Videla, A.
    Marzoratti, L.
    Luna, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [35] Nationwide case-control study of risk factors and outcomes for community-acquired sepsis
    Lindstrom, Ann-Charlotte
    Eriksson, Mikael
    Martensson, Johan
    Oldner, Anders
    Larsson, Emma
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [36] Community-acquired Klebsiella pneumoniae pneumonia in ICU: a multicenter retrospective study
    Grosjean, Vincent
    Gressens, Simon B.
    Pham, Tai
    Gaudry, Stephane
    Ait-Oufella, Hafid
    De Prost, Nicolas
    Mayaux, Julien
    Guerot, Emmanuel
    Leflon-Guibout, Veronique
    Mayer, Noemie
    Bert, Frederic
    Gault, Nathalie
    Massonnaud, Clement R.
    Roux, Damien
    ANNALS OF INTENSIVE CARE, 2024, 14 (01)
  • [37] Early identification of severe community-acquired pneumonia: a retrospective observational study
    Grudzinska, Frances S.
    Aldridge, Kerrie
    Hughes, Sian
    Nightingale, Peter
    Parekh, Dhruv
    Bangash, Mansoor
    Dancer, Rachel
    Patel, Jaimin
    Sapey, Elizabeth
    Thickett, David R.
    Dosanjh, Davinder P.
    BMJ OPEN RESPIRATORY RESEARCH, 2019, 6 (01)
  • [38] Predicting treatment failure in patients with community acquired pneumonia: a case-control study
    Ignacio Martin-Loeches
    Xavier Valles
    Rosario Menendez
    Oriol Sibila
    Beatriz Montull
    Catia Cilloniz
    Antonio Artigas
    Antoni Torres
    Respiratory Research, 15
  • [39] Frailty and loss of rectus femoris muscle thickness in elderly patients hospitalized with community-acquired pneumonia - A case-control study
    Touge, Hirokazu
    Tomita, Katsuyuki
    Ueda, Yasuto
    Matsunami, Keiji
    Kitaura, Tsuyoshi
    Nishii, Shizuka
    Sakai, Hiromitsu
    Yamasaki, Akira
    Kawasaki, Yuji
    Shimizu, Eiji
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [40] Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients A Matched Case-Control Study
    Cilloniz, Catia
    Torres, Antoni
    Manzardo, Christian
    Gabarrus, Albert
    Ambrosioni, Juan
    Salazar, Adriana
    Garcia, Felipe
    Ceccato, Adrian
    Mensa, Josep
    de la Bella Casa, Jorge Puig
    Moreno, Asuncion
    Miro, Jose M.
    CHEST, 2017, 152 (02) : 295 - 303